CCS Publications  2022

Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Le, M. P., Peytavin, G., Staub, T., Greil, R., Guedj, J., Paiva, J. A., Costagliola, D., Yazdanpanah, Y., Burdet, C., Mentre, F. and DisCoVeRy Study, G. (2022). Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 22, 209-221.

Aggarwal, R. R., Rottey, S., Aparicio, A., Greil, R., Reimers, M. A., Sandhu, S. K., Zhang, Y. R., Salvati, M. and Sadraei, N. H. (2022). Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol 40.

Akimova, E., Gassner, F. J., Greil, R., Zaborsky, N. and Geisberger, R. (2022). Detecting Bacterial-Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia. Int J Mol Sci 23.

Alhayek, A., Abdelsamie, A. S., Schonauer, E., Camberlein, V., Hutterer, E., Posselt, G., Serwanja, J., Blochl, C., Huber, C. G., Haupenthal, J., Brandstetter, H., Wessler, S. and Hirsch, A. K. H. (2022a). Discovery and Characterization of Synthesized and FDA-Approved Inhibitors of Clostridial and Bacillary Collagenases. J Med Chem 65, 12933-12955.

Alhayek, A., Khan, E. S., Schonauer, E., Dainghaus, T., Shafiei, R., Voos, K., Han, M. K. L., Ducho, C., Posselt, G., Wessler, S., Brandstetter, H., Haupenthal, J., Del Campo, A. and Hirsch, A. K. H. (2022b). Inhibition of Collagenase Q1 of Bacillus cereus as a Novel Antivirulence Strategy for the Treatment of Skin-Wound Infections. Adv Ther (Weinh) 5, 2100222.

Altendorfer, B., Unger, M. S., Poupardin, R., Hoog, A., Asslaber, D., Gratz, I. K., Mrowetz, H., Benedetti, A., de Sousa, D. M. B., Greil, R., Egle, A., Gate, D., Wyss-Coray, T. and Aigner, L. (2022). Transcriptomic Profiling Identifies CD8(+) T Cells in the Brain of Aged and Alzheimer's Disease Transgenic Mice as Tissue-Resident Memory T Cells. J Immunol 209, 1272-1285.

Barbero, F., Michelini, S., Moriones, O. H., Patarroyo, J., Rosell, J., M, F. G., Vitali, M., Martin, L., Canals, F., Duschl, A., Horejs-Hoeck, J., Mondragon, L., Bastus, N. G. and Puntes, V. (2022). Role of Common Cell Culture Media Supplements on Citrate-Stabilized Gold Nanoparticle Protein Corona Formation, Aggregation State, and the Consequent Impact on Cellular Uptake. Bioconjug Chem 33, 1505-1514.

Bartsch, R., Gampenrieder, S. P., Rinnerthaler, G., Petru, E., Egle, D., Petzer, A., Balic, M., Pluschnig, U., Sliwa, T. and Singer, C. (2022). Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wien Klin Wochenschr 134, 63-72.

Bernegger, S., Hutterer, E., Zarzecka, U., Schmidt, T. P., Huemer, M., Widlroither, I., Posselt, G., Skorko-Glonek, J. and Wessler, S. (2022a). E-Cadherin Orthologues as Substrates for the Serine Protease High Temperature Requirement A (HtrA). Biomolecules 12.

Bernegger, S., Jarzab, M., Wessler, S. and Posselt, G. (2022b). Proteolytic Landscapes in Gastric Pathology and Cancerogenesis. Int J Mol Sci 23.

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I., Rabitsch, W., Kwong, Y. L., Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Muller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., Del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jager, U., Borchmann, P. and Westin, J. R. (2022). Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 386, 629-639.

Boccuni, L., Podgorschek, E., Schmiedeberg, M., Platanitis, E., Traxler, P., Fischer, P., Schirripa, A., Novoszel, P., Nebreda, A. R., Arthur, J. S. C., Fortelny, N., Farlik, M., Sexl, V., Bock, C., Sibilia, M., Kovarik, P., Muller, M. and Decker, T. (2022). Stress signaling boosts interferon-induced gene transcription in macrophages. Sci Signal 15, eabq5389.

Bolik, J., Krause, F., Stevanovic, M., Gandrass, M., Thomsen, I., Schacht, S. S., Rieser, E., Muller, M., Schumacher, N., Fritsch, J., Wichert, R., Galun, E., Bergmann, J., Roder, C., Schafmayer, C., Egberts, J. H., Becker-Pauly, C., Saftig, P., Lucius, R., Schneider-Brachert, W., Barikbin, R., Adam, D., Voss, M., Hitzl, W., Kruger, A., Strilic, B., Sagi, I., Walczak, H., Rose-John, S. and Schmidt-Arras, D. (2022). Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. J Exp Med 219.

Bottinger, K., Esser-Skala, W., Segl, M., Herwig, C. and Huber, C. G. (2022). At-line quantitative profiling of monoclonal antibody products during bioprocessing using HPLC-MS. Anal Chim Acta 1207, 339813.

Burtness, B., Rischin, D., Greil, R., Soulieres, D., Tahara, M., de Castro, G., Jr., Psyrri, A., Brana, I., Baste, N., Neupane, P., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Ge, J., Swaby, R. F., Gumuscu, B. and Harrington, K. (2022). Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 40, 2321-2332.

Byun, J., Han, Y., Li, Y., Xia, J., Long, E., Choi, J., Xiao, X., Zhu, M., Zhou, W., Sun, R., Bosse, Y., Song, Z., Schwartz, A., Lusk, C., Rafnar, T., Stefansson, K., Zhang, T., Zhao, W., Pettit, R. W., Liu, Y., Li, X., Zhou, H., Walsh, K. M., Gorlov, I., Gorlova, O., Zhu, D., Rosenberg, S. M., Pinney, S., Bailey-Wilson, J. E., Mandal, D., de Andrade, M., Gaba, C., Willey, J. C., You, M., Anderson, M., Wiencke, J. K., Albanes, D., Lam, S., Tardon, A., Chen, C., Goodman, G., Bojeson, S., Brenner, H., Landi, M. T., Chanock, S. J., Johansson, M., Muley, T., Risch, A., Wichmann, H. E., Bickeboller, H., Christiani, D. C., Rennert, G., Arnold, S., Field, J. K., Shete, S., Le Marchand, L., Melander, O., Brunnstrom, H., Liu, G., Andrew, A. S., Kiemeney, L. A., Shen, H., Zienolddiny, S., Grankvist, K., Johansson, M., Caporaso, N., Cox, A., Hong, Y. C., Yuan, J. M., Lazarus, P., Schabath, M. B., Aldrich, M. C., Patel, A., Lan, Q., Rothman, N., Taylor, F., Kachuri, L., Witte, J. S., Sakoda, L. C., Spitz, M., Brennan, P., Lin, X., McKay, J., Hung, R. J. and Amos, C. I. (2022). Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet 54, 1167-1177.

Diel, I. J., Greil, R., Janssen, J., Kluike, C. W., Behera, B., Abbasi, A., Seesaghur, A., Kellner, M., Jaeger, C., Bjorklof, K., Tomova, A. and Haslbauer, F. (2022). Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Support Care Cancer 30, 9267-9278.

Ettinger, M., Burner, T., Lackner, A., Schoeftner, L. C., Holzgruber, J., Gruber, R., Guenova, E., Schuetz-Bergmayr, M., Fischer, T., Gratz, I. K., Kimeswenger, S. and Hoetzenecker, W. (2022). Precision medicine approach in a rare case of autosomal recessive congenital ichthyosis. J Dtsch Dermatol Ges 20, 1651-1653.

Faltus, C., Lahnsteiner, A., Barrdahl, M., Assenov, Y., Husing, A., Bogatyrova, O., Laplana, M., Johnson, T., Muley, T., Meister, M., Warth, A., Thomas, M., Plass, C., Kaaks, R. and Risch, A. (2022). Identification of NHLRC1 as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS). Int J Mol Sci 23.

Folprecht, G., Reinacher-Schick, A., Weitz, J., Lugnier, C., Kraeft, A. L., Wisser, S., Aust, D. E., Weiss, L., von Bubnoff, N., Kramer, M., Thiede, C. and Tannapfel, A. (2022). The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). Clin Colorectal Canc 21, 170-174.

Frauenlob, T., Neuper, T., Mehinagic, M., Dang, H. H., Boraschi, D. and Horejs-Hoeck, J. (2022). Helicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS. Front Immunol 13, 847958.

Gampenrieder, S. P., Dezentje, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortes Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruche, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Goncalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortes, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., Greil, R. and Group, A. S. (2022a). Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group. ESMO Open 8, 100747.

Gampenrieder, S. P., Dezentje, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Serrano, C. S., Costa, D. A., Blondeaux, E., Del Mastro, L., Bertucci, F., Goncalves, A., Bartsch, R., Deleuze, A., Salgado, A. C., Vitorino, M., Tinchon, C., Pecen, L., Rinnerthaler, G. and Greil, R. (2022b). Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT). Ann Oncol 33, S208-S208.

Gampenrieder, S. P., Pircher, M., Fesl, C., Rinnerthaler, G., Mlineritsch, B., Greil-Ressler, S., Steger, G. G., Sagaster, V., Fitzal, F., Exner, R., Devyatko, Y., Balic, M., Stoger, H., Suppan, C., Bauernhofer, T., Singer, C. F., Pfeiler, G., Seifert, M., Helfgott, R., Heck, D., Rumpold, H., Kwasny, W., Wieder, U., Gnant, M. and Greil, R. (2022c). Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Breast Care (Basel) 17, 137-145.

Gampenrieder, S. P., Steiner, M., Hufnagl, C., Hackl, H., Rinnerthaler, G., Westphal, T., Huemer, F., Monzo-Fuentes, C., Morre, P., Hauser-Kronberger, C. and Greil, R. (2022d). Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. Ann Oncol 33, S141-S141.

Gerger, A., Eisterer, W., Fuxius, S., Bastian, S., Koeberle, D., Welslau, M., Sanoyan, D. A., Maas, C., Uhlig, J., Fenchel, K., Greil, R., E, V. D. H., Agocs, G. R., Weide, R., Schwager, M., Reichenbach, F., Modest, D. P. and Fritsch, R. (2022). Retrospective Analysis of Treatment Pathways in Patients With BRAF(V600E)-mutant Metastatic Colorectal Carcinoma - MORSE(CRC). Anticancer Res 42, 4773-4785.

Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E. M., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P. and Viale, G. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 33, 534-543.

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., Pfeiler, G., Miller, K. D., Colleoni, M., Suga, J. M., Rubovsky, G., Bliss, J. M., Mayer, I. A., Singer, C. F., Nowecki, Z., Hahn, O., Thomson, J., Wolmark, N., Amillano, K., Rugo, H. S., Steger, G. G., Hernando Fernandez de Aranguiz, B., Haddad, T. C., Perello, A., Bellet, M., Fohler, H., Metzger Filho, O., Jallitsch-Halper, A., Solomon, K., Schurmans, C., Theall, K. P., Lu, D. R., Tenner, K., Fesl, C., DeMichele, A., Mayer, E. L., groups, P. and investigators (2022). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 40, 282-293.

Gomes, F. G., Andrade, A. C., Wolf, M., Hochmann, S., Krisch, L., Maeding, N., Regl, C., Poupardin, R., Ebner-Peking, P., Huber, C. G., Meisner-Kober, N., Schallmoser, K. and Strunk, D. (2022). Synergy of Human Platelet-Derived Extracellular Vesicles with Secretome Proteins Promotes Regenerative Functions. Biomedicines 10.

Greil, R., Lin, U. N., Murthy, K. R., Abramson, V., Anders, C., Bachelot, T., Bedard, L. P., Borges, V., Cameron, D., Carey, L., Chien, J. A., Curigliano, G., DiGiovanna, P. M., Gelmon, K., Hortobagyi, G., Hurvitz, S., Krop, I., Loi, S., Loibl, S., Mueller, V., Oliveira, M., Paplomata, E., Pegram, M., Slamon, D., Zelnak, A., Ramos, J., Feng, W. and Winer, E. (2022). Updated Results of Tucatinib versus Placebo in Combination with Trastuzumab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB). Geburtsh Frauenheilk 82, E4-E5.

group, E. U.-R. i., Diallo, A., Troseid, M., Simensen, V. C., Boston, A., Demotes, J., Olsen, I. C., Chung, F., Paiva, J. A., Hites, M., Ader, F., Arribas, J. R., Baratt-Due, A., Melien, O., Tacconelli, E., Staub, T., Greil, R., Tsiodras, S., Briel, M., Esperou, H., Mentre, F., Eustace, J., Saillard, J., Delmas, C., LeMestre, S., Dumousseaux, M., Costagliola, D., Rottingen, J. A. and Yazdanpanah, Y. (2022). Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clin Microbiol Infect 28, 1-5.

Harbeck, N., Wrobel, D., Zaiss, M., Guth, D., Distelrath, A., Terhaag, J., Lorenz, A., Bartsch, R., Breitenstein, U., Schwitter, M., Balic, M., Jackisch, C., Muller, V., Rinnerthaler, G., Schmidt, M., Zaman, K., Schinkothe, T. and Luftner, D. (2022). Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC). Ann Oncol 33, S157-S157.

Harzschel, A., Li, L., Krenn, P. W., Szenes-Nagy, E., Andrieux, G., Bayer, E., Pfeifer, D., Polcik, L., Denk, U., Hopner, J. P., Karabatak, E., Danner, D. J., Tangermann, S., Kenner, L., Jumaa, H., Greil, R., Borries, M., Ruppert, R., Maity, P. C. and Hartmann, T. N. (2022). Kindlin-3 maintains marginal zone B cells but confines follicular B cell activation and differentiation. J Leukoc Biol 111, 745-758.

Hinterholzer, A., Moises, J., Regl, C., Schwap, S., Rapp, E., Huber, C. G. and Schubert, M. (2022). Unambiguous identification of alpha-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy. MAbs 14, 2132977.

Hoppe, I. J., Prommegger, B., Uhl, A., Lohrig, U., Huber, C. G. and Brandstetter, H. (2022). The Fluorescent Enzyme Cascade Detects Low Abundance Protein Modifications Suitable for the Assembly of Functionally Annotated Modificatome Databases. Chembiochem 23, e202200399.

Huemer, F., Hecht, S., Scharinger, B., Schlintl, V., Rinnerthaler, G., Schlick, K., Heregger, R., Melchardt, T., Wimmer, A., Muhlbacher, I., Koch, O. O., Neureiter, D., Klieser, E., Seyedinia, S., Beheshti, M., Greil, R. and Weiss, L. (2022). Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol. J Cancer Res Clin Oncol.

Johnson, L., Aglas, L., Punz, B., Dang, H. H., Christ, C., Pointner, L., Wenger, M., Hofstaetter, N., Hofer, S., Geppert, M., Andosch, A., Ferreira, F., Horejs-Hoeck, J., Duschl, A. and Himly, M. (2023). Mechanistic insights into silica nanoparticle-allergen interactions on antigen presenting cell function in the context of allergic reactions. Nanoscale 15, 2262-2275.

Klughammer, J., Romanovskaia, D., Nemc, A., Posautz, A., Seid, C. A., Schuster, L. C., Keinath, M. C., Lugo Ramos, J. S., Kosack, L., Evankow, A., Printz, D., Kirchberger, S., Erguner, B., Datlinger, P., Fortelny, N., Schmidl, C., Farlik, M., Skjaerven, K., Bergthaler, A., Liedvogel, M., Thaller, D., Burger, P. A., Hermann, M., Distel, M., Distel, D. L., Kubber-Heiss, A. and Bock, C. (2023). Comparative analysis of genome-scale, base-resolution DNA methylation profiles across 580 animal species. Nat Commun 14, 232.

Kuemmel, S., Campone, M., Loirat, D., Lopez, R. L., Beck, J. T., De Laurentiis, M., Im, S. A., Kim, S. B., Kwong, A., Steger, G. G., Adelantado, E. Z., Duhoux, F. P., Greil, R., Kuter, I., Lu, Y. S., Tibau, A., Ozguroglu, M., Scholz, C. W., Singer, C. F., Vega, E., Wimberger, P., Zamagni, C., Couillebault, X. M., Fan, L., Guerreiro, N., Mataraza, J., Sand-Dejmek, J. and Chan, A. (2022). A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res 28, 106-115.

Leisch, M., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Kiesl, D., Vallet, S., Egle, A., Melchardt, T., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F., Drost, M., Greil, R. and Pleyer, L. (2022). Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers (Basel) 14.

Li, Y., Xiao, X., Li, J., Byun, J., Cheng, C., Bosse, Y., McKay, J., Albanes, D., Lam, S., Tardon, A., Chen, C., Bojesen, S. E., Landi, M. T., Johansson, M., Risch, A., Bickeboller, H., Wichmann, H. E., Christiani, D. C., Rennert, G., Arnold, S., Goodman, G., Field, J. K., Davies, M. P. A., Shete, S. S., Le Marchand, L., Melander, O., Brunnstrom, H., Liu, G., Hung, R. J., Andrew, A. S., Kiemeney, L. A., Shen, H., Sun, R., Zienolddiny, S., Grankvist, K., Johansson, M., Caporaso, N., Teare, D. M., Hong, Y. C., Lazarus, P., Schabath, M. B., Aldrich, M. C., Schwartz, A. G., Gorlov, I., Purrington, K., Yang, P., Liu, Y., Han, Y., Bailey-Wilson, J. E., Pinney, S. M., Mandal, D., Willey, J. C., Gaba, C., Brennan, P., Amos, C. I. and consortium, I.-I. l. c. (2022). Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk. Hum Mol Genet 31, 2831-2843.

Luciano, M., Krenn, P. W. and Horejs-Hoeck, J. (2022). The cytokine network in acute myeloid leukemia. Front Immunol 13, 1000996.

Mayr, B., Reich, B., Greil, R. and Niebauer, J. (2022). The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy. Cancer Med 11, 4946-4953.

Minichsdorfer, C., Fuereder, T., Leutner, M., Singer, C. F., Kacerovsky-Strobl, S., Egle, D., Greil, R., Balic, M., Fitzal, F., Pfeiler, G., Frantal, S., Bartsch, R. and Gnant, M. (2022). Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. ESMO Open 7, 100426.

Moises, J. E., Regl, C., Hinterholzer, A., Huber, C. G. and Schubert, M. (2022). Unambiguous Identification of Glucose-Induced Glycation in mAbs and other Proteins by NMR Spectroscopy. Pharm Res.

Moyo, T. K., Mendler, J. H., Itzykson, R., Kishtagari, A., Solary, E., Seegmiller, A. C., Gerds, A. T., Ayers, G. D., Dezern, A. E., Nazha, A., Valent, P., van de Loosdrecht, A. A., Onida, F., Pleyer, L., Cirici, B. X., Tibes, R., Geissler, K., Komrokji, R. S., Zhang, J., Germing, U., Steensma, D. P., Wiseman, D. H., Pfeilstoecker, M., Elena, C., Cross, N. C. P., Luebbert, M., Mesa, R. A., Sanz, G. F., Platzbecker, U., Patnaik, M. M., Padron, E., Santini, V., Fenaux, P., Savona, M. R., Kiladjian, J. J., Montalban-Bravo, G. and Grp, M. M. I. W. (2022). The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. Bmc Cancer 22.

Muller, M., Saunders, C., Senftleben, A., Heidbuechel, J. P. W., Halwachs, B., Bolik, J., Hedemann, N., Roder, C., Bauerschlag, D., Rose-John, S. and Schmidt-Arras, D. (2022). Tetraspanin 8 Subfamily Members Regulate Substrate-Specificity of a Disintegrin and Metalloprotease 17. Cells 11.

Munir, T., Giannopoulos, K., Jurczak, W., Simkovic, M., Shadman, M., Osterborg, A., Laurenti, L., Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trneny, M., Brander, D. M., Flinn, I. W., Grosicki, S., Verner, E., Kahl, B. S., Ghia, P., Li, J. Y., Tian, T., Zhou, L., Marimpietri, C., Paik, J. C., Cohen, A., Huang, J., Brown, J. R., Robak, T. and Tam, C. S. (2022). SEQUOIA: Results of a Phase 3 Randomised Study of Zanubrutinib versus Bendamustine plus Rituximab in Patients with Treatment-Naive Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Brit J Haematol 197, 95-96.

Neumayer, B., Neureiter, D., Klieser, E., Huemer, F., Weiss, L., Greil, R., Djanani, A., Oberhuber, G. and Schlick, K. (2022). The influence of pancreatic regression characteristics on outcome of neoadjuvant treated pancreatic cancer in two Austrian university centres. Virchows Arch 481, S135-S136.

Neuper, T., Frauenlob, T., Posselt, G. and Horejs-Hoeck, J. (2022). Beyond the gastric epithelium - the paradox of Helicobacter pylori-induced immune responses. Curr Opin Immunol 76, 102208.

Nowakowski, G. S., Yoon, D. H., Peters, A., Mondello, P., Joffe, E., Fleury, I., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, P. L., Trotman, J., Huang, D., Waltl, E. E., Winderlich, M., Kurukulasuriya, N. C., Ambarkhane, S., Hess, G. and Salles, G. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res 28, 4003-4017.

Pleyer, L. and Sekeres, M. A. (2022). An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes. Lancet Haematol 9, e714-e716.

Punz, B., Johnson, L., Geppert, M., Dang, H. H., Horejs-Hoeck, J., Duschl, A. and Himly, M. (2022). Surface Functionalization of Silica Nanoparticles: Strategies to Optimize the Immune-Activating Profile of Carrier Platforms. Pharmaceutics 14.

Rathje, F., Klingler, S. and Aberger, F. (2022). Organoids for Modeling (Colorectal) Cancer in a Dish. Cancers (Basel) 14.

Razis, E., Escudero, M. J., Palmieri, C., Mueller, V., Bartsch, R., Rossi, G., Gampenrieder, S. P., Kolberg, H. C., Zdenkowski, N., Pavic, M., Connolly, R. M., Rosset, L., Arcuri, J., Tesch, H., Vallejos, C., Retamales, J., Musolino, A., Del Mastro, L., Christodoulou, C., Aebi, S., Paluch-Shimon, S., Gupta, S., Ohno, S., Macpherson, I., Ekholm, M., Zaman, K., Vidal, M., Chakiba, C., Fumagalli, D., Thulin, A., Witzel, I., Kotecki, N., Gil-Gil, M. and Linderholm, B. (2022). Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO Open 7, 100483.

Reitermaier, R., Ayub, T., Staller, J., Kienzl, P., Fortelny, N., Vieyra-Garcia, P. A., Worda, C., Fiala, C., Staud, C., Eppel, W., Scharrer, A., Krausgruber, T. and Elbe-Burger, A. (2022). The molecular and phenotypic makeup of fetal human skin T lymphocytes. Development 149.

Rinnerthaler, G., Singer, C., Petru, E., Egle, D., Petzer, A., Pluschnig, U., Gampenrieder, S. P., Pfeiler, G., Gnant, M., Grunberger, B., Krippl, P., Strasser-Weippl, K., Suppan, C., Brunner, C., Pusch, R., Sandholzer, M., Balic, M. and Bartsch, R. (2022). Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update. Wien Klin Wochenschr 134, 683-692.

Rischin, D., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., de Castro, G., Jr., Psyrri, A., Brana, I., Neupane, P., Bratland, A., Fuereder, T., Hughes, B. G. M., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. W., Hong, R. L., Mendoza, R. G., Jia, L., Chirovsky, D., Norquist, J., Jin, F. and Burtness, B. (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 128, 105815.

Roeder, F., Gerum, S., Hecht, S., Huemer, F., Jager, T., Kaufmann, R., Klieser, E., Koch, O. O., Neureiter, D., Emmanuel, K., Sedlmayer, F., Greil, R. and Weiss, L. (2022). How We Treat Localized Rectal Cancer-An Institutional Paradigm for Total Neoadjuvant Therapy. Cancers (Basel) 14.

Rosenberg, N., Van Haele, M., Lanton, T., Brashi, N., Bromberg, Z., Adler, H., Giladi, H., Peled, A., Goldenberg, D. S., Axelrod, J. H., Simerzin, A., Chai, C., Paldor, M., Markezana, A., Yaish, D., Shemulian, Z., Gross, D., Barnoy, S., Gefen, M., Amran, O., Claerhout, S., Fernandez-Vaquero, M., Garcia-Beccaria, M., Heide, D., Shoshkes-Carmel, M., Schmidt Arras, D., Elgavish, S., Nevo, Y., Benyamini, H., Tirnitz-Parker, J. E. E., Sanchez, A., Herrera, B., Safadi, R., Kaestner, K. H., Rose-John, S., Roskams, T., Heikenwalder, M. and Galun, E. (2022). Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol 77, 1631-1641.

Rosenberger, A., Muttray, N., Hung, R. J., Christiani, D. C., Caporaso, N. E., Liu, G., Bojesen, S. E., Le Marchand, L., Albanes, D., Aldrich, M. C., Tardon, A., Fernandez-Tardon, G., Rennert, G., Field, J. K., Davies, M. P. A., Liloglou, T., Kiemeney, L. A., Lazarus, P., Wendel, B., Haugen, A., Zienolddiny, S., Lam, S., Schabath, M. B., Andrew, A. S., Duell, E. J., Arnold, S. M., Goodman, G. E., Chen, C., Doherty, J. A., Taylor, F., Cox, A., Woll, P. J., Risch, A., Muley, T. R., Johansson, M., Brennan, P., Landi, M. T., Shete, S. S., Amos, C. I., Bickeboller, H. and Consortium, I.-I. (2022). Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer. Eur J Med Res 27, 14.

Samadi, N., Koidl, L., Salzmann, M., Klems, M., Komatitsch, N., Schaffer, D., Weidmann, E., Duschl, A., Horejs-Hoeck, J. and Untersmayr, E. (2022). Food Allergen Nitration Enhances Safety and Efficacy of Oral Immunotherapy in Food Allergy. Nutrients 14.

Schamschula, E., Lahnsteiner, A., Assenov, Y., Hagmann, W., Zaborsky, N., Wiederstein, M., Strobl, A., Stanke, F., Muley, T., Plass, C., Tummler, B. and Risch, A. (2022). Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells. Epigenetics 17, 837-860.

Schlick, K., Neumayer, B. and Neureiter, D. (2022). What is the management of resected cholangiocarcinoma in terms of intra- and postoperative status of tumor margins and lymph nodes? A current view. Expert Rev Gastroenterol Hepatol 16, 1019-1022.

Schlintl, V., Huemer, F., Rinnerthaler, G., Melchardt, T., Winder, T., Reimann, P., Riedl, J., Amann, A., Eisterer, W., Romeder, F., Piringer, G., Ilhan-Mutlu, A., Woll, E., Greil, R. and Weiss, L. (2022). Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. Bmc Cancer 22, 51.

Schurz, M., Danmayr, J., Jaritsch, M., Klinglmayr, E., Benirschke, H. M., Matea, C. T., Zimmerebner, P., Rauter, J., Wolf, M., Gomes, F. G., Kratochvil, Z., Heger, Z., Miller, A., Heuser, T., Stanojlovic, V., Kiefer, J., Plank, T., Johnson, L., Himly, M., Blochl, C., Huber, C. G., Hintersteiner, M. and Meisner-Kober, N. (2022). EVAnalyzer: High content imaging for rigorous characterisation of single extracellular vesicles using standard laboratory equipment and a new open-source ImageJ/Fiji plugin. J Extracell Vesicles 11, e12282.

Singer, C. F., Abcsg, Holst, F., Steurer, S., Burandt, E. C., Lax, S. F., Jakesz, R., Rudas, M., Stoger, H., Greil, R., Abcsg, Sauter, G., Filipits, M., Abcsg, Simon, R., Gnant, M. and Abcsg (2022a). Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer. Clin Cancer Res 28, 4112-4120.

Singer, C. F., Egle, D., Greil, R., Petru, E., Ohler, L., Balic, M., Tinchon, C., Pfeiler, G., Marhold, M., Brunner, C., Haider, K., Galid, A., Pluschnig, U., Haslbauer, F., Hubalek, M., Redl, A., Flatschacher, J., Uthman, S., Mraz, B. and Bartsch, R. (2022b). REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis. Ann Oncol 33, S217-S217.

Starzer, A. M., Heller, G., Tomasich, E., Melchardt, T., Feldmann, K., Hatziioannou, T., Traint, S., Minichsdorfer, C., Schwarz-Nemec, U., Nackenhorst, M., Mullauer, L., Preusser, M., Berghoff, A. S. and Fuereder, T. (2022). DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer 10.

Tam, C. S., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Jurczak, W., Simkovic, M., Shadman, M., Osterborg, A., Laurenti, L., Walker, P., Opat, S., Chan, H., Ciepluch, H., Greil, R., Tani, M., Trneny, M., Brander, D. M., Flinn, I. W., Grosicki, S., Verner, E., Tedeschi, A., Li, J., Tian, T., Zhou, L., Marimpietri, C., Paik, J. C., Cohen, A., Huang, J., Robak, T. and Hillmen, P. (2022). Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23, 1031-1043.

Tesanovic, S., Krenn, P. W. and Aberger, F. (2022). Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside. Front Cell Dev Biol 10, 944760.

Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trneny, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y., Greil, R., Mykhalska, L., Bergua-Burgues, J. M., Cheung, M. C., Pinto, A., Shin, H. J., Hapgood, G., Munhoz, E., Abrisqueta, P., Gau, J. P., Hirata, J., Jiang, Y., Yan, M., Lee, C., Flowers, C. R. and Salles, G. (2022a). Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386, 351-363.

Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trneny, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y. Q., Greil, R., Mykhalska, L., Miguel, J., Burgues, B., Cheung, M. C., Pinto, A., Shin, H. J., Hapgood, G., Munhoz, E., Abrisqueta, P., Gau, J. P., Hirata, J., Jiang, Y. W., Yan, M., Lee, C., Flowers, C., Salles, G. and Collins, G. (2022b). Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study. Brit J Haematol 197, 14-16.

Urwanisch, L., Unger, M. S., Sieberer, H., Dang, H. H., Neuper, T., Regl, C., Vetter, J., Schaller, S., Winkler, S. M., Kerschbamer, E., Weichenberger, C. X., Krenn, P. W., Luciano, M., Pleyer, L., Greil, R., Huber, C. G., Aberger, F. and Horejs-Hoeck, J. (2023). The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells. Cancers (Basel) 15.

von der Heyde, E., Burkle, D., Forstbauer, H., Hubner, G., Schmidt, B., Schroder, J., Distelrath, A., Wierecky, J., Stubs, P., Kisro, J., Welslau, M., Muller-Huesmann, H., Gohler, T., Krammer-Steiner, B., Schwaner, I., Hering-Schubert, C., Gerger, A., Greil, R., Jacobasch, L., Reichenbach, F., Stintzing, S. and Prager, G. (2022). Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC. Ann Oncol 33, S248-S248.

Wang, D., Zhang, T., Madunic, K., de Waard, A. A., Blochl, C., Mayboroda, O. A., Griffioen, M., Spaapen, R. M., Huber, C. G., Lageveen-Kammeijer, G. S. M. and Wuhrer, M. (2022). Glycosphingolipid-Glycan Signatures of Acute Myeloid Leukemia Cell Lines Reflect Hematopoietic Differentiation. J Proteome Res 21, 1029-1040.

Watzenboeck, M. L., Gorki, A. D., Quattrone, F., Gawish, R., Schwarz, S., Lambers, C., Jaksch, P., Lakovits, K., Zahalka, S., Rahimi, N., Starkl, P., Symmank, D., Artner, T., Pattaroni, C., Fortelny, N., Klavins, K., Frommlet, F., Marsland, B. J., Hoetzenecker, K., Widder, S. and Knapp, S. (2022). Multi-omics profiling predicts allograft function after lung transplantation. Eur Respir J 59.

Weiss, L. (2022). ESMO 2021-highlights in colorectal cancer. Memo-Mag Eur Med Onc 15, 114-116.

Westphal, T., Gampenrieder, S. P., Rinnerthaler, G., Balic, M., Posch, F., Dandachi, N., Hauser-Kronberger, C., Reitsamer, R., Sotlar, K., Radl, B., Suppan, C., Stoger, H. and Greil, R. (2022). Transferring MINDACT to Daily Routine: Implementation of the 70-Gene Signature in Luminal Early Breast Cancer - Results from a Prospective Registry of the Austrian Group Medical Tumor Therapy (AGMT). Breast Care (Basel) 17, 1-9.

Woess, K., Sun, Y., Morio, H., Stierschneider, A., Kaufmann, A., Hainzl, S., Trattner, L., Kocher, T., Tockner, B., Leb-Reichl, V., Steiner, M., Brachtl, G., South, A. P., Bauer, J. W., Reichelt, J., Furihata, T., Wally, V., Koller, U., Pinon Hofbauer, J. and Guttmann-Gruber, C. (2022). Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer. Int J Mol Sci 23.

Wolf, M., Poupardin, R. W., Ebner-Peking, P., Andrade, A. C., Blochl, C., Obermayer, A., Gomes, F. G., Vari, B., Maeding, N., Eminger, E., Binder, H. M., Raninger, A. M., Hochmann, S., Brachtl, G., Spittler, A., Heuser, T., Ofir, R., Huber, C. G., Aberman, Z., Schallmoser, K., Volk, H. D. and Strunk, D. (2022). A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation. J Extracell Vesicles 11, e12207.

Yang, W., Liu, H., Zhang, R., Freedman, J. A., Han, Y., Hung, R. J., Brhane, Y., McLaughlin, J., Brennan, P., Bickeboeller, H., Rosenberger, A., Houlston, R. S., Caporaso, N. E., Landi, M. T., Brueske, I., Risch, A., Christiani, D. C., Amos, C. I., Chen, X., Patierno, S. R. and Wei, Q. (2022). Deciphering associations between three RNA splicing-related genetic variants and lung cancer risk. NPJ Precis Oncol 6, 48.

Zhang, R., Shen, S., Wei, Y., Zhu, Y., Li, Y., Chen, J., Guan, J., Pan, Z., Wang, Y., Zhu, M., Xie, J., Xiao, X., Zhu, D., Li, Y., Albanes, D., Landi, M. T., Caporaso, N. E., Lam, S., Tardon, A., Chen, C., Bojesen, S. E., Johansson, M., Risch, A., Bickeboller, H., Wichmann, H. E., Rennert, G., Arnold, S., Brennan, P., McKay, J. D., Field, J. K., Shete, S. S., Le Marchand, L., Liu, G., Andrew, A. S., Kiemeney, L. A., Zienolddiny-Narui, S., Behndig, A., Johansson, M., Cox, A., Lazarus, P., Schabath, M. B., Aldrich, M. C., Dai, J., Ma, H., Zhao, Y., Hu, Z., Hung, R. J., Amos, C. I., Shen, H., Chen, F. and Christiani, D. C. (2022). A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians. J Thorac Oncol 17, 974-990.

Zhou, Q., Gampenrieder, S. P., Frantal, S., Rinnerthaler, G., Singer, C. F., Egle, D., Pfeiler, G., Bartsch, R., Wette, V., Pichler, A., Petru, E., Dubsky, P. C., Bago-Horvath, Z., Fesl, C., Rudas, M., Stahlberg, A., Graf, R., Weber, S., Dandachi, N., Filipits, M., Gnant, M., Balic, M. and Heitzer, E. (2022). Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. Clin Cancer Res 28, 697-707.